




Overview of Medivation and Dimebon

Sarah Noonberg M.D., Ph.D.
Director, Clinical Development

Medivation, Inc.

- Publicly-traded biopharmaceutical company
- Founded in 2003
- Headquarters in San Francisco
 - Offices in Chile and India
- Mission is to efficiently develop innovative therapies for serious diseases with significant unmet medical need.
- Current pipeline:
 - Dimebon in Huntington's disease and Alzheimer's disease
 - MDV3100 in prostate cancer
- www.medivation.com

History of Dimebon



Major Activities in 2008



H • S • G
HUNTINGTON • STUDY • GROUP

Phase 2 Trial of Dimebon in Patients with Mild-to-Moderate Huntington's Disease (DIMOND)

- Safety/tolerability over 3 months of treatment
- Effect on Huntington's disease symptoms
- Enrollment complete; initial results expected in July
- If results encouraging, phase 3 program to follow





Phase 3 Trial of Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease

- Effect on Alzheimer's disease symptoms over 6 months of treatment
- Safety/tolerability
- Enrollment ongoing

Dimebon Has Potent Effects on Mitochondria

Human cell




Images from [http:// www.wikipedia.org](http://www.wikipedia.org) and <http://www.coolschool.ca/lor/BI12/unit3/U03L03.htm>

So...

- What are mitochondria?
 - Small structures inside of cells that turn nutrients from food into fuel
 - Tiny “gas” stations that provide fuel to cells for normal function
- What do mitochondria have to do with Huntington’s disease?
 - Genetic defect is believed to interfere with normal mitochondrial function
 - Brain cells may not have enough energy to function properly
- How might Dimebon benefit Huntington’s disease patients?
 - Dimebon is believed to improve mitochondrial function
 - Improved mitochondrial function may translate into healthier brain cells and improved symptoms

Important Laboratory Effects of Dimebon


- Dimebon improves neuron survival under experimental conditions
 - Ionomycin (neurotoxin)
 - Low serum conditions (cellular stress)
 - β -amyloid (Alzheimer's disease)



Ann NY Acad Sci, 939: 425-35, 2001


The Huntington's Disease Fly Model

- Dimebon improves neuron survival in a fly model of Huntington's disease




Drosophila melanogaster (Fruitfly)

A. Eye Structure



Dimebon Protected Photoreceptor Neurons



Important Clinical Effects of Dimebon

- Huntington's disease:
 - Dimebon was generally well tolerated over 8 days of treatment
 - Results supported moving forward to the current Phase 2 study

- Alzheimer's disease:
 - Dimebon improved thinking, behavior, and overall function after one year of treatment
 - General signs and symptoms were improved or stabilized in ~70% of patients
 - Benefits were seen as early as 3 months and were stable or increased over time
 - Dimebon was generally well tolerated
 - Results supported moving forward to the current confirmatory Phase 3 study

Similarities Between Alzheimer's Disease and Huntington's Disease

- Both diseases have similar progressive symptoms
 - Difficulty in thinking, changes in behavior, loss of independence
- Both diseases involve the accumulation of abnormal proteins in brain cells
 - β -amyloid vs. huntingtin protein
- Both diseases involve abnormalities in mitochondria function contributing to brain cell death
- Our hypothesis: Benefits demonstrated in Alzheimer's disease will translate into benefits in Huntington's disease

Looking Ahead in our HD Program

- In the coming days:
 - Completing dosing in the DIMOND study
- In the coming weeks:
 - Analyzing initial safety and efficacy data from the DIMOND study
 - Announcing initial results (expected in July)
- In the coming months:
 - Full analysis of the DIMOND study
 - If warranted, progressing to Phase 3 studies with Dimebon

Lastly....

Patients

Physicians

Thank you

Caregivers

Study Personnel

